Back to Search
Start Over
Slow reduction of IP-10 Levels predicts HBeAg seroconversion in chronic hepatitis B patients with 5 years of entecavir treatment
- Source :
- Scientific Reports
- Publication Year :
- 2016
- Publisher :
- Springer Science and Business Media LLC, 2016.
-
Abstract
- The aim of this study was to determine the correlation between dynamic changes in serum cytokine/chemokine expression levels in response to entecavir (ETV) treatment and HBV e antigen (HBeAg) seroconversion in patients with chronic hepatitis B (CHB). Four cytokines (interleukin [IL]-4, IL-6, IL-8, and interferon-γ) and five chemokines (macro-phage inflammatory protein [MIP]-1α, MIP-1β, platelet derived growth factor-BB, and interferon-inducible protein 10 [IP-10]) before ETV therapy and at 3, 6, 12, 24, 36 and 60 months during therapy in 105 CHB patients were analyzed. The results showed that the low decrease rate of IP-10 levels after 1 year of ETV treatment was an independent predictor of HBeAg seroconversion at year 5 (Hazard ratio = 0.972). The area under the receiver operating characteristic curves for the decrease rate of IP-10 levels after 1 year of treatment to discriminate a year-5 HBeAg seroconversion was 0.752 (p = 0.005). The results indicate that higher IP-10 level at year one of ETV treatment is associated with an increased probability of HBeAg seroconversion. Quantification of IP-10 during ETV treatment may help to predict long-term HBeAg seroconversion in patients with CHB.
- Subjects :
- Adult
Male
0301 basic medicine
medicine.medical_specialty
Chemokine
Time Factors
Gastroenterology
Article
03 medical and health sciences
Hepatitis B, Chronic
0302 clinical medicine
Chronic hepatitis
Antigen
Internal medicine
medicine
Humans
Hepatitis B e Antigens
Seroconversion
Multidisciplinary
Receiver operating characteristic
biology
business.industry
Interleukin
Entecavir
Middle Aged
Chemokine CXCL10
030104 developmental biology
HBeAg
Immunology
biology.protein
Female
030211 gastroenterology & hepatology
business
Follow-Up Studies
medicine.drug
Subjects
Details
- ISSN :
- 20452322
- Volume :
- 6
- Database :
- OpenAIRE
- Journal :
- Scientific Reports
- Accession number :
- edsair.doi.dedup.....f8febb185e693e2423e89e1d4780d19b